Total
0
Shares
Image Sourced ShutterStock
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Amplia Therapeutics (ATX) has signed a term sheet for a collaboration agreement with the Garvan Institute of Media Research in Sydney
  • The term sheet maps out a collaborative research and clinical development program to treat patients with pancreatic cancer using Amplia’s FAK inhibitor, AMP945
  • The collaboration will combine the Garvan Institute’s research strength in FAK biology and its extensive clinical research network, with Amplia’s proprietary FAK inhibitors and drug development capability
  • The final Collaboration Agreement is expected to be signed within 90 days
  • Amplia is up 3.85 per cent, trading at 27 cents

Amplia Therapeutics (ATX) has signed a term sheet for a collaboration agreement with the Garvan Institute of Media Research in Sydney.  

The term sheet maps out a collaborative research and clinical development program, focused on the use of Amplia’s FAK inhibitor, AMP945, to treat patients with pancreatic cancer.

The collaboration will initially look at new treatment regiments and patient selection strategies for Amplia’s clinical trials of AMP945 in pancreatic cancer patients later this year.

The collaboration will combine the Garvan Institute’s research strength in FAK biology and its extensive clinical research network with Amplia’s proprietary FAK inhibitors and drug development capability.

“The purpose of this collaboration is to optimise our planned clinical program for AMP945,” said Amplia’s CEO and Managing Director, Dr John Lambert.

“Clearly, Garvan’s team has an unsurpassed understanding of FAK biology and access to an extensive clinical network. By leveraging Garvan’s deep understanding of the different biological roles that FAK can play, we aim to optimise the design of our planned clinical trials, recruit the right pancreatic cancer patients and treat them in the right way, giving AMP945 the best chance for success.”

Professor Paul Timpson, Cancer Research Theme Leader at Garvan will be the lead scientist in the collaborative research program, after collaborating with Amplia for over a year.

The terms of the agreement are confidential but include future payments by Amplia to Garvan based on AMP945 achieving specified clinical, regulatory and commercial sales milestones.

The final Collaboration Agreement is expected to be signed within 90 days.

Amplia is up 3.85 per cent, trading at 27 cents at 1:20 pm AEDT.  

ATX by the numbers
More From The Market Herald
Alcidion Group (ASX:ALC) - Group Managing Director, Kate Quirke

" Alcidion (ASX:ALC) to raise $55m & acquire Silverlink

Alcidion (ALC) has announced plans to raise $55 million and buy patient software specialists, Silverlink PCS Software.
Actinogen Medical (ASX:ACW) - CEO & Managing Director, Dr Steven Gourlay

" Actinogen Medical (ASX:ACW) partners with Oxford University

Actinogen (ACW) has announced a collaboration with Oxford University researchers to investigate Xanamem and a condition called mild autonomous cortisol secretion (MACS).
Neuren Pharmaceuticals (ASX:NEU) - CEO, Jon Pilcher

" Neuren Pharmaceuticals (ASX:NEU) soars on ‘positive’ Rett syndrome trial results

Neuren Pharmaceuticals’ (NEU) shares have soared following positive top-line results from a phase three study on Rett syndrome.

" Recce Pharmaceuticals (ASX:RCE) spikes amid trial update

Shares in Recce Pharmaceuticals (RCE) have spiked amid a positive update in the clinical trial for the treatment of burn wound infections.